Patents Assigned to Benovus Bio, Inc.
  • TUMOR SELECTIVE ANTIBODIES SPECIFIC TO ONCOFETAL ANTIGEN/IMMATURE LAMININ RECEPTOR PROTEIN
    Publication number: 20160229918
    Abstract: Disclosed are high affinity antibodies or antigen binding fragments thereof, which bind an epitope that lies within the C terminal region of oncofetal antigen (OFA)/immature laminin receptor protein (iLRP), and which do not substantially cross-react with mature OFA/LRP. The antibodies may be conjugated to cytotoxic moieties to enhance their therapeutic efficacy. Methods of making the antibodies and therapeutic and diagnostic uses thereof are also disclosed.
    Type: Application
    Filed: July 11, 2014
    Publication date: August 11, 2016
    Applicants: Benovus Bio, Inc., South Alabama Medical Science Foundation
    Inventors: Kent J. Johnson, Alton C. Morgan, Joseph A. Sinkule, James Varani, Joseph H. Coggin (Deceased), James W. Rohrer (Deceased), Adel L. Barsoum
  • ONCOFETAL ANTIGEN/IMMATURE LAMININ RECEPTOR ANTIBODIES FOR DIAGNOSTIC AND CLINICAL APPLICATIONS
    Publication number: 20150218273
    Abstract: The present invention relates to antibodies against Oncofetal Antigen/immature Laminin receptor protein (OFA/iLRP) that can be used singly or in conjunction to detect or treat OFA/iLRP-related diseases. More specifically, the antibodies can be used for several purposes including: (i) detecting and measuring OFA/iLRP in different biofluids; and (ii) using OFA/iLRP with an antibody directed against the monomeric form and its associated diseases.
    Type: Application
    Filed: April 17, 2015
    Publication date: August 6, 2015
    Applicant: BENOVUS BIO, INC.
    Inventor: Eric W. Olle
  • TUMOR SELECTIVE ANTIBODIES SPECIFIC TO ONCOFETAL ANTIGEN/IMMATURE LAMININ RECEPTOR PROTEIN
    Publication number: 20150218287
    Abstract: Disclosed are high affinity antibodies or antigen-binding fragments thereof, which bind an epitope that lies within the C-terminal region of oncofetal antigen (OFA)/immature laminin receptor protein (iLRP), and which do not substantially cross-react with mature OFA/LRP. The antibodies may be conjugated to cytotoxic moieties to enhance their therapeutic efficacy. Methods of making the antibodies and therapeutic and diagnostic uses thereof are also disclosed.
    Type: Application
    Filed: February 4, 2015
    Publication date: August 6, 2015
    Applicants: BENOVUS BIO, INC., SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION
    Inventors: Kent J. Johnson, Alton C. Morgan, Joseph A. Sinkule, James Varani, Joseph H. Coggin, JR., James W. Rohrer, Adel L. Barsoum
  • Oncofetal antigen/immature laminin receptor antibodies for diagnostic and clinical applications
    Patent number: 9012155
    Abstract: The present invention relates to antibodies against Oncofetal Antigen/immature Laminin receptor protein (OFA/iLRP) that can be used singly or in conjunction to detect or treat OFA/iLRP-related diseases. More specifically, the antibodies can be used for several purposes including: (i) detecting and measuring OFA/iLRP in different biofluids; and (ii) using OFA/iLRP with an antibody directed against the monomeric form and its associated diseases.
    Type: Grant
    Filed: July 22, 2013
    Date of Patent: April 21, 2015
    Assignee: Benovus Bio, Inc.
    Inventor: Eric W. Olle